

## Brief Communications

Zinc Selectively Blocks Neurosteroid-Sensitive Extrasynaptic  $\delta$ GABA<sub>A</sub> Receptors in the HippocampusChase Matthew Carver, Shu-Hui Chuang, and  Doodipala Samba Reddy

Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&amp;M University Health Science Center, Bryan, Texas 77807

Zinc ( $Zn^{2+}$ ) is an essential cofactor in mammalian cells and neurons.  $Zn^{2+}$  is released from synaptic vesicles of certain nerve terminals in the hippocampus during neuronal activity.  $Zn^{2+}$  has been shown to inhibit synaptic GABA<sub>A</sub> receptors and alter the hippocampal network excitability. However, the ability of  $Zn^{2+}$  to block extrasynaptic receptors remains unclear. Endogenous neurosteroids, such as allopregnanolone (AP), regulate neuronal excitability by allosteric activation of synaptic and extrasynaptic GABA<sub>A</sub> receptors. Neurosteroids activate extrasynaptic  $\delta$ GABA<sub>A</sub> receptor-mediated tonic inhibition in dentate gyrus granule cells (DGGCs), thereby contributing to the regulation of downstream circuit excitability. Here we report a novel inhibitory role of  $Zn^{2+}$  at neurosteroid-sensitive, extrasynaptic  $\delta$ GABA<sub>A</sub> receptors by electrophysiological recordings in DGGCs from adult mice.  $Zn^{2+}$  displayed a concentration-dependent, reversible noncompetitive blockade of AP-sensitive tonic current in DGGCs ( $IC_{50}$ , 16  $\mu$ M). Tonic current was fully blocked by  $Zn^{2+}$ , akin to the GABA<sub>A</sub> receptor antagonist gabazine.  $Zn^{2+}$  inhibition of tonic current was lacking in DGGCs from  $\delta$ -subunit knock-out mice. Moreover, AP-activated synaptic receptor-mediated phasic currents were not affected by  $Zn^{2+}$ . Finally, intrahippocampal infusion of  $Zn^{2+}$  elicited rapid epileptiform activity and significantly blocked the antiseizure activity of AP in the kindling model of epilepsy. Thus,  $Zn^{2+}$  inhibition of neurosteroid-sensitive, extrasynaptic GABA<sub>A</sub> receptors in the hippocampus has direct implications in many brain hyperexcitability conditions, such as seizures, epileptogenesis, and epilepsy.  $Zn^{2+}$  interactions may aid to further understand the physiology of extrasynaptic GABA<sub>A</sub> receptors.

**Key words:** epilepsy; extrasynaptic; GABA receptor; neurosteroid; tonic inhibition; zinc

## Significance Statement

$Zn^{2+}$  is most abundant in the synaptic vesicles of hippocampal mossy fibers.  $Zn^{2+}$  release occurs with neuronal excitation, including seizure events, and exerts powerful excitability effects in the hippocampus circuits.  $Zn^{2+}$  inhibits synaptic GABA<sub>A</sub> receptors, but its interaction is less well appreciated at the extrasynaptic receptors, which respond sensitively to endogenous neurosteroids. Here, we describe selective functional blockade by  $Zn^{2+}$  of neurosteroid-sensitive, extrasynaptic GABA<sub>A</sub> receptors in the mouse hippocampus dentate gyrus, a key region associated with epilepsy and memory disorders. By demonstrating that extracellular  $Zn^{2+}$  prevents neurosteroid augmentation of tonic current and protection against limbic seizures, our findings provide novel implications of this potential antagonistic interaction in a variety of neurological conditions.

## Introduction

Many human enzymes incorporate or use zinc ( $Zn^{2+}$ ) as a cofactor to catalyze key biochemical reactions. A key role for the metal emerged with discovery of chelatable  $Zn^{2+}$  localization in synap-

tic vesicles in the brain (Frederickson, 1989; Danscher, 1996).  $Zn^{2+}$  is present in high level in synaptic vesicles of glutamatergic terminals, including hippocampal mossy fibers. It is released during neuronal activity, and its uptake and loading into synaptic vesicle are regulated by  $Zn^{2+}$  transporter ZnT3 (Assaf and Cung, 1984; Cole et al., 1999; Molnár and Nadler, 2001).  $Zn^{2+}$  has been shown to modulate certain ion channels and ligand-gated receptors (Harrison and Gibbons, 1994).  $Zn^{2+}$  is abundant within hippocampal mossy fibers that project from the dentate gyrus to the CA3 (Frederickson et al., 1983) and can be visualized by Timm's staining of the hippocampus (Kay, 2003). Thus,  $Zn^{2+}$  is suggested to play an important modulatory role in epilepsy (Coulter, 2000), and  $Zn^{2+}$ -abundant mossy fiber sprouting is a classical morphological index of limbic epileptogenesis (Cavazos et al., 1991).  $Zn^{2+}$  negatively modulates GABAergic inhibition at

Received Sept. 9, 2015; revised May 24, 2016; accepted May 31, 2016.

Author contributions: C.M.C. and D.S.R. designed research; C.M.C., S.-H.C., and D.S.R. performed research; C.M.C. and D.S.R. analyzed data; C.M.C. and D.S.R. wrote the paper.

This work was supported in part by National Institutes of Health Grant R01NS051398 to D.S.R. and Texas Brain and Spine Institute graduate fellowship to C.M.C. We thank Bryan Clossen for outstanding kindling assistance; and the reviewers for their insightful suggestions.

The authors declare no competing financial interests.

Correspondence should be addressed to Dr. Doodipala Samba Reddy, Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M University Health Science Center, 2008 Medical Research and Education Building, 8447 State Highway 47, Bryan, TX 77807-3260. E-mail: reddy@medicine.tamhsc.edu.

DOI:10.1523/JNEUROSCI.3393-15.2016

Copyright © 2016 the authors 0270-6474/16/368070-08\$15.00/0

mossy fiber synaptic varicosities that release GABA (Ruiz et al., 2004; Bitanirwe and Cunningham, 2009). Excessive release of Zn<sup>2+</sup> has been reported in epilepsy (Takeda et al., 1999), and it can elicit excitatory and proconvulsant effects (Foresti et al., 2008).

Zn<sup>2+</sup> is a GABA<sub>A</sub> receptor antagonist and displays differential sensitivities at two receptor subtypes (Smart et al., 1991; Stórus-tovu and Ebert, 2006). In the hippocampus dentate gyrus,  $\gamma$ -containing receptors are located synaptically and produce phasic currents. Dentate gyrus granule cells (DGGCs) have high expression of extrasynaptic,  $\delta$ -containing receptors responsible for continuous tonic inhibition (Glykys et al., 2008). Synaptic and extrasynaptic receptors are distinct in GABA affinity and efficacy, channel kinetics, and pharmacological sensitivity to allosteric modulators, such as neurosteroids (Reddy, 2011; Wu et al., 2013; Carver et al., 2014). Three discrete binding sites contribute to Zn<sup>2+</sup> inhibition, including one site within the channel pore and two at the external amino terminus of the  $\alpha$ - $\beta$  interfaces; the inclusion of the  $\gamma$ -subunit disrupts two of the sites, resulting in reduction in sensitivity (Hosie et al., 2003). Although the  $\delta$ -containing receptors are more sensitive to Zn<sup>2+</sup> block than  $\gamma$ -containing receptors (Mangan et al., 2005), the ability of Zn<sup>2+</sup> to modify extrasynaptic  $\delta$ GABA<sub>A</sub> receptors is poorly understood.

Neurosteroids, such as allopregnanolone (AP), are positive allosteric modulators of synaptic and extrasynaptic GABA<sub>A</sub> receptors and exhibit a greater potency for extrasynaptic  $\delta$ -containing receptors (Spigelman et al., 2003; Stell et al., 2003; Reddy and Jian, 2010). AP potentiates tonic current in DGGCs and provides robust protection against a variety of seizures and status epilepticus (Carver et al., 2014; Reddy and Estes, 2016). Zn<sup>2+</sup> and neurosteroids have preferential affinity for  $\delta$ -containing receptors (Carver and Reddy, 2013, 2016). However, the physiological interaction between Zn<sup>2+</sup> and neurosteroids at extrasynaptic GABA<sub>A</sub> receptors remains unclear. We hypothesized that extracellular Zn<sup>2+</sup> prevents neurosteroid activation of extrasynaptic  $\delta$ GABA<sub>A</sub> receptor-mediated tonic inhibition and thereby impairs their ability to promote neuroprotection and seizure suppression. In this study, we tested this hypothesis by directly investigating Zn<sup>2+</sup> blockade of extrasynaptic  $\delta$ GABA<sub>A</sub> receptor function using a combination of *in vitro* and *in vivo* electrophysiological techniques. Our results show that Zn<sup>2+</sup> selectively inhibits extrasynaptic  $\delta$ GABA<sub>A</sub> receptors and thereby totally prevents AP activation of tonic inhibition and seizure protection. These results highlight the potential role of Zn<sup>2+</sup> in modulating GABAergic tonic inhibition in the hippocampus.

## Materials and Methods

**Animals.** Adult male mice of 2–3 months age, maintained on hybrid C57BL/6–129SV background, were used for the study. Wild-type and GABA<sub>A</sub> receptor  $\delta$ -subunit knock-out (*Gabrd*<sup>-/-</sup>,  $\delta$ KO) mice were used for experiments. All animal procedures were performed in a protocol approved by the university's Institutional Animal Care and Use Committee.


**Hippocampal slice electrophysiology.** Transverse slices (300  $\mu$ m) of hippocampus were prepared from mice using standard technique, as reported previously (Carver et al., 2014). Mice were anesthetized with isoflurane, and brains were excised and placed in 3.5°C aCSF that composed of the following (in mM): 126 NaCl, 3 KCl, 0.5 CaCl<sub>2</sub>, 5 MgCl<sub>2</sub>, 26 NaHCO<sub>3</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 11 glucose, 0.3 kynurenic acid, pH adjusted to 7.35–7.40, with 95% O<sub>2</sub>/5% CO<sub>2</sub>, 305–315 mOsm/kg. Slices were cut with a vibratome (model 1500 with 900 Refrigeration System, Leica Microsystems). Hippocampal slices were maintained in oxygenated aCSF at 28°C for 60 min, and experiments were performed at 23°C. Neurons were visually identified with an Olympus BX51 microscope equipped with a

40 $\times$  water-immersion objective, infrared-differential interference contrast optics and camera. Recordings in hippocampus slice were performed in whole-cell patch-clamp configuration as described previously (Carver et al., 2014). Currents were recorded using an Axopatch 200B amplifier (Molecular Devices). Membrane capacitance, series resistance, and input resistance were monitored by applying 5 mV (100 ms) depolarizing voltage step from holding potential of –65 mV. Signals were low-pass filtered at 2 kHz and digitized at 10 kHz with Digidata 1440A system. Tonic current and miniature inhibitory postsynaptic currents (mIPSCs) of GABA<sub>A</sub> receptors were recorded in the presence of TTX (0.5  $\mu$ M, Na<sup>+</sup> channel blocker, and inhibition of action potential-evoked neurotransmitter release), APV (40  $\mu$ M, NMDA channel blocker), and DNQX (10  $\mu$ M, non-NMDA glutamate receptor blocker). The competitive antagonist gabazine (SR-95531, GBZ, 50  $\mu$ M) was added to perfusion at the conclusion of recordings to confirm block of GABAergic currents. Drugs were delivered to the bath chamber using a multichannel perfusion system (Automate Scientific).

Off-line analysis was performed with pClamp software, as described previously (Carver et al., 2014). Averaged tonic current shift and root-mean-square (RMS) noise amplitude were measured. GABA<sub>A</sub> receptor I<sub>tonic</sub> (tonic current) was expressed as the difference in holding current before and after application of gabazine (50  $\mu$ M) or Zn<sup>2+</sup> (1–1000  $\mu$ M). I<sub>tonic</sub> was measured and averaged in 100 ms each epoch with 1 s interval between 30 epochs. I<sub>RMS</sub> noise conductance was measured in 50 ms each epoch with 500 ms interval between 30 epochs during drug application. Changes in I<sub>tonic</sub> or I<sub>RMS</sub> are expressed in pA of current. For concentration comparisons, currents were normalized to membrane capacitance (pA/pF) as I<sub>tonic</sub> density. Synaptic currents were recorded and analyzed as previously described (Carver et al., 2014). The amplitude and decay time constants of mIPSCs were measured using MiniAnalysis software (Synaptosoft). Nonoverlapping events with single peaks were used to create an ensemble average mIPSC. A mean weighted decay time constant was determined from biexponential fitting function  $I(t) = A_1 \times e^{(-t/\tau_1)} + A_2 \times e^{(-t/\tau_2)}$  as  $\tau_w = (A_1 \times \tau_1 + A_2 \times \tau_2)/(A_1 + A_2)$ . For each electrophysiology experiment, 2–4 animals were used per group.

**Hippocampus kindling model of epilepsy.** Seizure experiments were conducted using hippocampus kindling model (Reddy and Mohan, 2011; Reddy et al., 2015). Mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). A bipolar electrode fixed to a guide cannula (Plastics One) was stereotaxically implanted in the right ventral hippocampus (2.9 mm posterior, 3.0 mm lateral, and 3.0 mm below dura). After postoperative recovery, animals were subjected to kindling stimulation (Reddy and Mohan, 2011). The electrographic afterdischarge (AD) threshold was determined by application of 1 ms biphasic rectangular pulses at 60 Hz for 1 s, in increments of 25  $\mu$ A using an isolated pulse stimulator (A-M Systems). AD duration was the total duration of electrographic spike activity (amplitude >2 $\times$  baseline) occurring in a rhythmic pattern at a frequency >1 Hz. Mice were stimulated at 125% AD threshold once per day until Stage 5 seizures were elicited on 3 consecutive days, considered the fully kindled state. The electrographic activity was recorded using Axoscope 8.0 software with Digidata 1322A interface (Molecular Devices) through a Grass CP511 preamplifier (Astro-Med). Behavioral seizures were rated according to Racine's scale as modified for mouse. One week after kindling, ZnCl<sub>2</sub> (10–1000  $\mu$ M) was dissolved in sterile saline and microinfused in 5  $\mu$ l volume directly into the hippocampus using a perfusion pump at 0.2  $\mu$ l/min. Mice were monitored for seizures and electrographic activity for at least 10 min. AP (s.c.) was administered 15 min before or after infusion of Zn<sup>2+</sup>. AP was dissolved in 20%  $\beta$ -cyclodextrin solution for subcutaneous injections. After each stimulation, mice were scored for protection based on the behavioral motor seizures and AD duration.

**Drugs and reagents.** All chemicals were purchased from Sigma-Aldrich unless otherwise specified. Drug solutions for slice recording were prepared as 2 mM stock solution in DMSO. They were diluted in the external perfusion solution to the desired concentration for electrophysiological use. DMSO concentration in final solution was <1%. AP was acquired



**Figure 1.** The neurosteroid AP-activated tonic currents are sensitive to Zn<sup>2+</sup> antagonism. **Ai, Aii,** Representative GABAergic tonic current recordings from WT DGGCs in the presence of GABA + AP, Zn<sup>2+</sup>, and gabazine (GBZ). Zn<sup>2+</sup> application inhibited AP modulation and produced a positive shift in  $I_{\text{tonic}}$ . **Aiii,** Zn<sup>2+</sup> wash-out reversed tonic potentiation by AP. **B,** Concentration response of 1 μM GABA + 0.3 μM AP-modulated, normalized  $I_{\text{tonic}}$  (pA/pF) to block by Zn<sup>2+</sup> (1–1000 μM). **C,** Fractional response of AP-modulated  $I_{\text{tonic}}$  due to Zn<sup>2+</sup>. \* $p$  < 0.05 versus maximal block due to saturating 50 μM gabazine. **D,**  $I_{\text{RMS}}$  channel conductance (pA) and percentage change of Zn<sup>2+</sup> blockade of AP-dependent  $I_{\text{RMS}}$ . AP indicates 1 μM GABA + 0.3 μM AP condition without Zn<sup>2+</sup>. \* $p$  < 0.05 versus AP  $I_{\text{RMS}}$ . **E,** Representative  $I_{\text{tonic}}$  recording from  $\delta$ -subunit knock-out DGGCs. **F,** Zn<sup>2+</sup> did not significantly shift  $I_{\text{tonic}}$  (pA) in  $\delta$ KO DGGCs. Recordings in whole-cell mode, voltage-clamped at –65 mV. Data are mean  $\pm$  SEM ( $n$  = 5–7 cells for each subgroup).

from Steraloids. Kynurenic acid was acquired from Tocris Bioscience. TTX was acquired from Calbiochem.


**Statistical analysis.** Group data are expressed as mean  $\pm$  SEM. Statistical comparisons of parametric measures, including electrophysiology data, were performed using an independent two-tailed Student's  $t$  test followed by Tukey's HSD test *post hoc*. Cumulative probability distributions of mIPSCs before and after Zn<sup>2+</sup> application were compared with the nonparametric Kolmogorov–Smirnov test. In all statistical tests, the criterion for statistical significance was  $p$  < 0.05, unless otherwise specified.

## Results

### Neurosteroid AP potentiation of tonic currents is selectively sensitive to negative modulation by Zn<sup>2+</sup>

We recorded neurosteroid-activated tonic currents from DGGCs in the hippocampus slice using whole-cell, voltage-clamp (–65 mV) electrophysiology (Fig. 1). We first investigated Zn<sup>2+</sup> block of endogenous  $I_{\text{tonic}}$  from nonpotentiated  $\delta$ GABA<sub>A</sub> receptors. In

recordings without exogenous GABA, 50 μM Zn<sup>2+</sup> produced 0.22  $\pm$  0.03 pA/pF positive shift, 100 μM Zn<sup>2+</sup> produced 0.26  $\pm$  0.10 pA/pF shift, and 50 μM of the competitive antagonist gabazine resulted in 0.53  $\pm$  0.10 pA/pF shift in  $I_{\text{tonic}}$  ( $n$  = 7 cells). This resulted in an overall mean 55.1  $\pm$  0.1% and 58.2  $\pm$  0.2% fractional block of total endogenous  $I_{\text{tonic}}$  by 50 and 100 μM Zn<sup>2+</sup>, respectively. To study neurosteroid AP potentiation of a physiological concentration of GABA (Włodarczyk et al., 2013), we recorded  $I_{\text{tonic}}$  at 0.2 μM GABA + 0.3 μM AP. AP induced negative shift in the holding current level and increased the RMS channel conductance as previously reported (Carver et al., 2014), but Zn<sup>2+</sup> (50 μM) application positively shifted AP-dependent  $I_{\text{tonic}}$  0.87  $\pm$  0.09 pA/pF ( $n$  = 7 cells) (Fig. 1Ai). To further demonstrate pharmacological sensitivity of Zn<sup>2+</sup> block of AP potentiation, 1 μM GABA + 0.3 μM AP effect on current was recorded. Subsequent application of Zn<sup>2+</sup> (0.1–1000 μM) resulted in



**Figure 2.** The neurosteroid AP-activated phasic currents are not sensitive to  $Zn^{2+}$  antagonism. **A**, Representative traces of phasic events by patch-clamp recordings from DGGCs in the presence of 1  $\mu$ M GABA, GABA + AP, and  $Zn^{2+}$ . GABA<sub>A</sub> receptor mIPSC activity was isolated using TTX, APV, and DNQX, and was completely blocked by gabazine. AP (0.3  $\mu$ M) potentiated synaptic current peak amplitude  $1.53 \pm 0.12$ -fold, but  $Zn^{2+}$  did not significantly alter the mIPSCs. **B**, Averaged mIPSC events in the presence of AP (solid line) and addition of  $Zn^{2+}$  (dashed line). **C**,  $Zn^{2+}$  did not significantly alter mean weighted decay kinetics ( $\tau_w$ ) of AP modulation. **D**, Cumulative probability curves for mIPSC amplitude plotted from all events during AP (solid line), 10  $\mu$ M  $Zn^{2+}$  (dotted line), and 100  $\mu$ M  $Zn^{2+}$  (dashed line). Amplitudes were not significantly different between AP and 10  $\mu$ M  $Zn^{2+}$  ( $p = 0.110$ ), or AP and 100  $\mu$ M  $Zn^{2+}$  ( $p = 0.191$ ) compared with Kolmogorov–Smirnov test. Recordings in whole-cell mode, voltage-clamped at  $-65$  mV. \* $p < 0.05$  versus baseline. Data are mean  $\pm$  SEM ( $n = 4$ –7 cells for each group and concentration, with 200–300 mIPSC events per cell and condition).

concentration-dependent block of  $I_{tonic}$ , measured as positive shift in the holding current level (Fig. 1*Aii*).  $Zn^{2+}$  wash-out rapidly reversed the  $I_{tonic}$  to the previously enhanced level by AP (Fig. 1*Aiii*).  $Zn^{2+}$ -induced block of AP-sensitive  $I_{tonic}$  is summarized in Figure 1*B*. Gabazine block of the AP-modulated  $I_{tonic}$  response was significantly greater than fractional block by  $Zn^{2+}$  at 1–100  $\mu$ M, but not at 1000  $\mu$ M (Fig. 1*C*). The  $IC_{50}$  value of  $Zn^{2+}$  blockade of tonic current was  $16.3 \pm 5.8$   $\mu$ M.  $Zn^{2+}$  significantly reduced the  $I_{RMS}$  channel conductance of AP modulation ranging from  $7.8 \pm 2.3\%$  reduction in 1  $\mu$ M  $Zn^{2+}$  ( $p = 0.0095$ ) to  $30.0 \pm 4.2\%$  in 1000  $\mu$ M  $Zn^{2+}$  ( $p = 0.0003$ ) (Fig. 1*D*). In DGGCs from  $\delta$ GABA<sub>A</sub> receptor knock-out mice,  $Zn^{2+}$  application had no significant effect on  $I_{tonic}$  (Fig. 1*E,F*).


#### Neurosteroid AP potentiation of phasic currents is insensitive to negative allosteric modulation by $Zn^{2+}$

We investigated the effect of  $Zn^{2+}$  on AP-activated postsynaptic phasic currents in DGGCs (Fig. 2). Previous studies report that  $Zn^{2+}$  significantly reduces phasic mIPSC amplitude and kinetics of GABA-evoked currents (Barberis et al., 2000; Manzerra et al.,

2001). Further reports indicate that, in response to 60  $\mu$ M  $Zn^{2+}$ , GABA<sub>A</sub> receptor IPSCs are diminished in amplitude but not decay kinetics (Mangan et al., 2005). Therefore, we analyzed mIPSC events (in the presence of TTX) before and during 10 or 100  $\mu$ M  $Zn^{2+}$  modulation of GABA<sub>A</sub> receptors. AP (0.3  $\mu$ M) significantly increased the weighted decay time constant ( $\tau_w$ ) and peak amplitude of mIPSCs from DGGCs (Fig. 2). We did not observe  $Zn^{2+}$  depression of AP-modulated mIPSC weighted decay time constant (Fig. 2*B,C*), and mean and cumulative distribution amplitudes were not significantly different (Fig. 2*D*). These findings indicate that  $Zn^{2+}$ -induced blockade of AP-mediated GABAergic current in DGGCs is highly selective for extrasynaptic  $\delta$ GABA<sub>A</sub> receptors, which mediate the majority of tonic inhibition ( $\sim 95\%$ ) in DGGCs.

#### The $Zn^{2+}$ chelator TPEN prevents the $Zn^{2+}$ blockade of neurosteroid-sensitive tonic currents

To further demonstrate the reversible effects of  $Zn^{2+}$  blockade of  $\delta$ GABA<sub>A</sub> receptors, we investigated tonic current in the presence of *N,N,N',N'*-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), a



**Figure 3.** TPEN inhibits the  $\text{Zn}^{2+}$  antagonism of AP-sensitive tonic currents. **A**, Representative  $I_{\text{tonic}}$  recordings before and after application of  $\text{Zn}^{2+}$  chelator TPEN (100  $\mu\text{M}$ ) in modulation of 0.2  $\mu\text{M}$  GABA + 0.3  $\mu\text{M}$  AP, or in coapplication with 50  $\mu\text{M}$   $\text{Zn}^{2+}$ . TPEN prevented  $\text{Zn}^{2+}$  blockade of AP-sensitive current, and  $I_{\text{tonic}}$  exhibited significant enhancement by TPEN in hyperpolarization of the holding current level. Quantification of  $I_{\text{tonic}}$  was achieved relative to complete block by gabazine (GBZ). **B**,  $I_{\text{tonic}}$  density shift (pA/pF) in the presence of  $\text{Zn}^{2+}$  and/or TPEN, with positive values as block of AP-sensitive  $I_{\text{tonic}}$  and negative values as enhancement of  $I_{\text{tonic}}$ . **C**, Representative trace demonstrating the enhancement of AP-sensitive  $I_{\text{tonic}}$  by TPEN, followed by the inability of  $\text{Zn}^{2+}$  to block extrasynaptic receptors in the presence of 100  $\mu\text{M}$  TPEN in the same cell. **A**, **C**, Dashed lines indicate average holding current level throughout each drug application. \* $p < 0.05$  versus AP +  $\text{Zn}^{2+}$ . Data are mean  $\pm$  SEM ( $n = 5$ –8 cells per group).

membrane-permeable, high-affinity  $\text{Zn}^{2+}$  chelator (Gordey et al., 1995; Meeusen et al., 2012).  $\text{Zn}^{2+}$  (50  $\mu\text{M}$ ) blocked  $I_{\text{tonic}}$  of DGGCs perfused with 0.2  $\mu\text{M}$  GABA + 0.3  $\mu\text{M}$  AP, resulting in a positive shift of current  $0.87 \pm 0.09$  pA/pF. Such  $\text{Zn}^{2+}$  block was prevented when 100  $\mu\text{M}$  TPEN was added to the perfusion, and DGGCs displayed  $-0.57 \pm 0.16$  pA/pF negative shift in  $I_{\text{tonic}}$  (Fig. 3B). The difference between  $\text{Zn}^{2+}$ -antagonized and TPEN-enhanced  $I_{\text{tonic}}$  was statistically significant ( $p < 0.001$ ,  $n = 7$ –8 cells per group) (Fig. 3B). Without  $\text{Zn}^{2+}$  added to perfusion, TPEN sustained negative shift of the AP-modulated  $I_{\text{tonic}}$   $-0.52 \pm 0.07$  pA/pF ( $n = 7$  cells) (Fig. 3A), indicating significant modulation of endogenous  $\text{Zn}^{2+}$  within the brain slice. The  $\text{Zn}^{2+}$  chelating effect by TPEN was also demonstrated in an alternative protocol, where  $\text{Zn}^{2+}$  was added to the slice immediately after TPEN (Fig. 3C).

### $\text{Zn}^{2+}$ elicits epileptiform seizures and inhibits the antiseizure effect of the neurosteroid AP in the kindling model of epilepsy


To directly examine the effect of  $\text{Zn}^{2+}$  on hippocampus hyperexcitability and seizures in epileptic animals, we generated fully kindled mice that exhibit consistent, Stage 5 (generalized) seizures. We then tested whether intrahippocampal  $\text{Zn}^{2+}$  (10–1000  $\mu\text{M}$ ) infusion promotes seizure susceptibility in fully kindled, epileptic mice before and after AP treatment (Fig. 4A*i*). The percentage of animals experiencing seizures was dose-dependent, with a smaller percentage of animals experienced generalized seizures due to either 10 or 100  $\mu\text{M}$   $\text{Zn}^{2+}$  compared with 1000  $\mu\text{M}$  infusion (Fig. 4B). High-dose  $\text{Zn}^{2+}$  (1000  $\mu\text{M}$ ) infusion rapidly elicited Stage 5 seizures in all mice tested within 2 min of infusion. After  $\text{Zn}^{2+}$  infusion, mice were injected with AP (5 mg/kg, s.c.) and electrically stimulated by kindling protocol. AP-treated mice infused with  $\text{Zn}^{2+}$ -free saline or 10  $\mu\text{M}$   $\text{Zn}^{2+}$  displayed reduced duration of synchronous AD (Fig. 4C,E) and significant protection from kindling seizures (Fig. 4D). Despite AP

treatment, 100–1000  $\mu\text{M}$   $\text{Zn}^{2+}$ -infused mice exhibited significantly greater AD durations and higher incidence of seizures. After 24 h washout of drug, electric stimulation resulted in the return of Stage 5 seizures in all animals, indicating the reversible effect of  $\text{Zn}^{2+}$  on kindling seizures. The 1000  $\mu\text{M}$   $\text{Zn}^{2+}$  infusion elicited seizures in 100% of animals and was used to test pretreatment with AP (1–10 mg/kg, s.c.) (Fig. 4A*ii*). AP-treated mice displayed dose-dependent protection against  $\text{Zn}^{2+}$ -induced seizures (Fig. 4B). Collectively, these results indicate that  $\text{Zn}^{2+}$  may play an important role in the modulation of seizures by anticonvulsant neurosteroids, such as AP, which are powerful activators of  $\delta$ GABA<sub>A</sub> receptors.

## Discussion

### $\text{Zn}^{2+}$ selectively inhibits extrasynaptic $\delta$ GABA<sub>A</sub> receptor-mediated tonic inhibition in the hippocampus

This study shows that  $\text{Zn}^{2+}$  is a highly selective negative modulator of neurosteroid-sensitive, extrasynaptic  $\delta$ GABA<sub>A</sub> receptors that are responsible for tonic inhibition in the dentate gyrus, a key limbic region associated with epilepsy and memory disorders.  $\text{Zn}^{2+}$  inhibition of neurosteroid seizure protection in epileptic animals is novel. These findings are consistent with a facilitator role for  $\text{Zn}^{2+}$  in excitability (Buhl et al., 1996), excitotoxicity (Choi et al., 1988), and seizure disorders (Cavazos et al., 1991; Coulter, 2000). Neurosteroid-positive modulators that target  $\delta$ GABA<sub>A</sub> receptors are being investigated as therapeutic agents for brain diseases (Whissel et al., 2015; Carver and Reddy, 2016). Neurosteroids have potent anticonvulsant effects in animal models and clinical trials (Reddy, 2011). Tonic inhibition is vital to control network excitability and seizure susceptibility (Carver et al., 2014), but physiological interaction of  $\text{Zn}^{2+}$  and neurosteroids at GABA<sub>A</sub> receptors has not been examined previously. We observed potent  $\text{Zn}^{2+}$  blockade of neurosteroid-sensitive tonic currents but not phasic currents. A previous study reported



**Figure 4.** Intrahippocampal Zn<sup>2+</sup> infusion completely prevents the antiseizure effect of the neurosteroid AP in fully kindled mice. **Ai**, Experimental paradigm and infusion protocol for saline or Zn<sup>2+</sup> delivery (10–1000 μM) 10 min before AP (5 mg/kg, s.c.) treatment and kindling stimulation. **Aii**, Seizure protection paradigm for AP (1–10 mg/kg, s.c.) treatment 15 min before Zn<sup>2+</sup>-induced (1000 μM) seizures. **B**, Percentage of each group of animals exhibiting seizure responses. Squares represent Zn<sup>2+</sup>-induced seizures. Circles represent kindling stimulation after infusion. The 1000 μM Zn<sup>2+</sup> elicited seizures in all mice, and pretreatment with AP reduced percentage of Zn<sup>2+</sup>-induced seizures. **C**, Electrographic recordings of kindling ADs. Arrows indicate stimulation-onset artifact. **D**, Kindling-induced seizures. **E**, AD duration after Zn<sup>2+</sup> infusion. Anticonvulsant effect of 5 mg/kg AP was inhibited by 100 and 1000 μM Zn<sup>2+</sup>. After 24 h washout, mice displayed Stage 5 seizures and similar AD duration to the control group. \**p* < 0.05 versus control group. Data are mean ± SEM (*n* = 6 mice per group).

inhibition of phasic currents by Zn<sup>2+</sup> (Ruiz et al., 2004); however, we demonstrate that neurosteroid-mediated GABA<sub>A</sub> receptor potentiation overcomes Zn<sup>2+</sup> depression of synaptic receptors. Because of the high affinity for  $\delta$ -containing receptors, Zn<sup>2+</sup> and neurosteroids influence inhibition through opposing action, albeit at different allosteric sites (Hosie et al., 2003). Our data suggest that Zn<sup>2+</sup> is a  $\delta$ -selective noncompetitive antagonist and

therefore hinders neurosteroid transduction of extrasynaptic GABA<sub>A</sub> channels.

**Physiological role of Zn<sup>2+</sup> blockade of neurosteroid-sensitive GABAergic tonic inhibition**

Zn<sup>2+</sup> may regulate hippocampal neuronal excitability through multiple pathways. The role of Zn<sup>2+</sup> in modulating neuronal

function may be quite different from its role in pathological states, such as epilepsy. The overall contribution of  $Zn^{2+}$  to excitability may be dependent on the net responses of inhibitory and excitatory targets. Epileptogenic proliferation of mossy fibers in the dentate gyrus could play a role in augmented  $Zn^{2+}$  release (Coulter, 2000).  $Zn^{2+}$  depletion has also been implicated in seizure susceptibility (Bitanirwe and Cunningham, 2009). The average plasma concentration of  $Zn^{2+}$  in adult humans is 14  $\mu$ M (Halsted and Smith, 1970). Higher levels of  $Zn^{2+}$  are evident in the brain with concentrations in excess of 10–20  $\mu$ M attained during phasic release of  $Zn^{2+}$  in the synaptic cleft (Vogt et al., 2000). Based on our electrophysiology studies, these concentrations are sufficient to block extrasynaptic  $\delta$ GABA<sub>A</sub> receptors ( $IC_{50} = 16 \mu$ M). In addition, the synaptic levels of  $Zn^{2+}$  may reach as high as 200–300  $\mu$ M in the hippocampus during seizures (Cavazos et al., 1991; Buhl et al., 1996), indicating the potential seizure-exacerbating ability of  $Zn^{2+}$ . In our attempt to demonstrate that chelation of endogenous  $Zn^{2+}$  in brain slices with TPEN can enhance tonic current, we observed a small but statistically significant effect of TPEN (Fig. 3B). In the dentate gyrus,  $Zn^{2+}$  inhibits the GABA<sub>A</sub> receptor current, as previously observed (Gordey et al., 1995; Ruiz et al., 2004). By elevation of dietary  $Zn^{2+}$  or conditions in which the blood–brain barrier is disrupted, peripheral  $Zn^{2+}$  could possibly contribute to total levels in the brain, exerting effects to block GABA<sub>A</sub> receptors. Inhibitory deficits and GABA<sub>A</sub> receptor plasticity resulting from epilepsy may also alter the targets of  $Zn^{2+}$  and neurosteroids (Kapur and Macdonald, 1997; Peng et al., 2004). Similarly,  $Cu^{2+}$  displays  $\delta$ -containing receptor selectivity, and excessive levels in Wilson's disease could decrease tonic inhibition (McGee et al., 2013), suggesting a pathophysiological shift in excitability.

### $Zn^{2+}$ promotes epileptiform seizures and antagonizes neurosteroid seizure protection

We sought to understand how  $Zn^{2+}$  affects seizure susceptibility in epilepsy. Microinfusion of  $Zn^{2+}$  directly into the hippocampus rapidly caused epileptiform discharges and generalized seizures in fully kindled mice. This is consistent with  $Zn^{2+}$  blockade of GABA<sub>A</sub> receptors, leading to hyperexcitability and epileptiform seizures originating within the hippocampus (Slevin et al., 1986), but contrary to an earlier report (Elsas et al., 2009). Our findings indicate that pretreatment with the neurosteroid AP blocks such proconvulsant actions triggered by  $Zn^{2+}$ . Similarly,  $Zn^{2+}$  blocks the antiseizure effects of systemically administered AP in fully kindled mice. These results are consistent with pharmacological antagonistic features of  $Zn^{2+}$  at extrasynaptic  $\delta$ GABA<sub>A</sub> receptors. It remains unclear whether the observed *in vivo* augmentation of seizure susceptibility is the result of  $Zn^{2+}$ -mediated inhibition of AP-induced tonic currents in DGGCs.  $Zn^{2+}$  also blocks  $\alpha_4\beta\gamma$ - and  $\alpha_1\beta\delta$ -containing GABA<sub>A</sub> receptors, albeit at lower sensitivities than  $\alpha_4\beta\delta$  isoforms (Brown et al., 2002). Specific  $\delta$ -subunit knock-out of DG interneurons decreases tonic inhibition and increases firing frequency that leads to decreased DGGC excitability and lower *in vivo* seizure susceptibility (Lee and Maguire, 2013). Thus, the effect of GABAergic block by  $Zn^{2+}$  may result in the disinhibition of  $\alpha_1\beta\delta$ -containing interneurons; however, we observed the net outcome of  $Zn^{2+}$  hippocampal infusion to be rapidly increased seizure activity. We have previously shown that  $\delta$ GABA<sub>A</sub> receptor knock-out mice lacking DGGC tonic current have greater seizure susceptibility, suggesting a key role for tonic inhibition in epilepsy (Carver et al., 2014).

In conclusion, these results provide strong evidence that  $Zn^{2+}$  selectively inhibits neurosteroid-sensitive tonic current in

DGGCs via reversible, noncompetitive blockade of extrasynaptic  $\delta$ GABA<sub>A</sub> receptors. There are currently few known selective inhibitors for extrasynaptic GABA<sub>A</sub> receptors. In this context,  $Zn^{2+}$  may represent a powerful tool to study the neurophysiology of extrasynaptic GABA<sub>A</sub> receptors and their modulation by endogenous neurosteroids (Villumsen et al., 2015). These results underscore the potential role of  $Zn^{2+}$  in modulating GABAergic tonic inhibition. Together, these findings have pathophysiological implications in many brain hyperexcitability conditions, such as seizures, epileptogenesis, and epilepsy and conditions with compromised neurovascular unit or  $Zn^{2+}$  transport pathways in the brain.

### References

- Assaf SY, Chung SH (1984) Release of endogenous  $Zn^{2+}$  from brain tissue during activity. *Nature* 308:734–736. [CrossRef Medline](#)
- Barberis A, Cherubini E, Mozrzymas JW (2000) Zinc inhibits miniature GABAergic currents by allosteric modulation of GABA<sub>A</sub> receptor gating. *J Neurosci* 20:8618–8627. [Medline](#)
- Bitanirwe BK, Cunningham MG (2009) Zinc: the brain's dark horse. *Synapse* 63:1029–1049. [CrossRef Medline](#)
- Brown N, Kerby J, Bonnert TP, Whiting PJ, Wafford KA (2002) Pharmacological characterization of a novel cell line expressing human  $\alpha_4\beta_3\delta$ GABA-A receptors. *Br J Pharmacol* 136:965–974. [CrossRef Medline](#)
- Buhl EH, Otis TS, Mody I (1996) Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model. *Science* 271:369–373. [CrossRef Medline](#)
- Carver CM, Reddy DS (2013) Neurosteroid interactions with synaptic and extrasynaptic GABA<sub>A</sub> receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. *Psychopharmacology* 230:151–188. [CrossRef Medline](#)
- Carver CM, Reddy DS (2016) Neurosteroid structure–activity relationships for functional activation of extrasynaptic  $\delta$ GABA-A receptors in the hippocampus. *J Pharmacol Exp Ther* 357:188–204. [CrossRef Medline](#)
- Carver CM, Wu X, Gangisetty O, Reddy DS (2014) Perimenstrual-like hormonal regulation of extrasynaptic  $\delta$ -containing GABA<sub>A</sub> receptors mediating tonic inhibition and neurosteroid sensitivity. *J Neurosci* 34:14181–14197. [CrossRef Medline](#)
- Cavazos JE, Golarai G, Sutula TP (1991) Mossy fiber synaptic reorganization induced by kindling: time course of development, progression, and permanence. *J Neurosci* 11:2795–2803. [Medline](#)
- Choi DW, Yokoyama M, Koh J (1988) Zinc neurotoxicity in cortical cell culture. *Neuroscience* 24:67–79. [CrossRef Medline](#)
- Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmiter RD (1999) Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. *Proc Natl Acad Sci U S A* 96:1716–1721. [CrossRef Medline](#)
- Coulter DA (2000) Mossy fiber zinc and temporal lobe epilepsy: pathological association with altered “epileptic”  $\gamma$ -aminobutyric acid A receptors in dentate granule cells. *Epilepsia* 41 [Suppl 6]:S96–S99.
- Danscher G (1996) The autometallographic zinc-sulphide method: a new approach involving *in vivo* creation of nanometer-sized zinc sulphide crystal lattices in zinc-enriched synaptic and secretory vesicles. *Histochem J* 28:361–373. [CrossRef Medline](#)
- Elsas SM, Hazany S, Gregory WL, Mody I (2009) Hippocampal zinc infusion delays the development of afterdischarges and seizures in a kindling model of epilepsy. *Epilepsia* 50:870–879. [CrossRef Medline](#)
- Foresti ML, Arisi GM, Fernandes A, Tilelli CQ, Garcia-Cairasco N (2008) Chelatable zinc modulates excitability and seizure duration in the amygdala rapid kindling model. *Epilepsy Res* 79:166–172. [CrossRef Medline](#)
- Frederickson CJ (1989) Neurobiology of zinc and zinc-containing neurons. *Int Rev Neurobiol* 31:145–238. [CrossRef Medline](#)
- Frederickson CJ, Klitenick MA, Manton WI, Kirkpatrick JB (1983) Cytoarchitectonic distribution of zinc in the hippocampus of man and the rat. *Brain Res* 273:335–339. [CrossRef Medline](#)
- Glykys J, Mann EO, Mody I (2008) Which GABA<sub>A</sub> receptor subunits are necessary for tonic inhibition in the hippocampus? *J Neurosci* 28:1421–1426. [CrossRef Medline](#)
- Gordey M, Kang M, Olsen RW, Spigelman I (1995) Zinc modulation of

- GABAA receptor-mediated chloride flux in rat hippocampal slices. *Brain Res* 691:125–132. [CrossRef Medline](#)
- Halsted JA, Smith JC Jr (1970) Plasma zinc in health and disease. *Lancet* 1:322–324. [CrossRef Medline](#)
- Harrison NL, Gibbons SJ (1994) Zn<sup>2+</sup>: an endogenous modulator of ligand- and voltage-gated ion channels. *Neuropharmacology* 33:935–952. [CrossRef Medline](#)
- Hosie AM, Dunne EL, Harvey RJ, Smart TG (2003) Zinc-mediated inhibition of GABA<sub>A</sub> receptors: discrete binding sites underlie subtype specificity. *Nat Neurosci* 6:362–369. [CrossRef Medline](#)
- Kapur J, Macdonald RL (1997) Rapid seizure-induced reduction of benzodiazepine and Zn<sup>2+</sup> sensitivity of hippocampal dentate granule cell GABA<sub>A</sub> receptors. *J Neurosci* 17:7532–7540. [Medline](#)
- Kay AR (2003) Evidence for chelatable zinc in the extracellular space of the hippocampus, but little evidence for synaptic release of Zn. *J Neurosci* 23:6847–6855. [Medline](#)
- Lee V, Maguire J (2013) Impact of inhibitory constraint of interneurons on neuronal excitability. *J Neurophysiol* 110:2520–2535. [CrossRef Medline](#)
- Mangan PS, Sun C, Carpenter M, Goodkin HP, Sieghart W, Kapur J (2005) Cultured hippocampal pyramidal neurons express two kinds of GABA<sub>A</sub> receptors. *Mol Pharmacol* 67:775–788. [CrossRef Medline](#)
- Manzerra P, Behrens MM, Canzoniero LM, Wang XQ, Heidinger V, Ichinose T, Yu SP, Choi DW (2001) Zinc induces a Src family kinase-mediated up-regulation of NMDA receptor activity and excitotoxicity. *Proc Natl Acad Sci U S A* 98:11055–11061. [CrossRef Medline](#)
- McGee TP, Houston CM, Brickley SG (2013) Copper block of extrasynaptic GABA<sub>A</sub> receptors in mature cerebellum and striatum. *J Neurosci* 33:13431–13435. [CrossRef Medline](#)
- Meeusen JW, Nowakowski A, Petering DH (2012) Reaction of metal-binding ligands with the zinc proteasome: zinc sensors and N, N, N', N'-tetrakis(2-pyridylmethyl)ethylenediamine. *Inorg Chem* 51:3625–3632. [CrossRef Medline](#)
- Molnár P, Nadler JV (2001) Synaptically-released zinc inhibits N-methyl-D-aspartate receptor activation at recurrent mossy fiber synapses. *Brain Res* 910:205–207. [CrossRef Medline](#)
- Peng Z, Huang CS, Stell BM, Mody I, Houser CR (2004) Altered expression of the  $\delta$  subunit of the GABA<sub>A</sub> receptor in a mouse model of temporal lobe epilepsy. *J Neurosci* 24:8629–8639. [CrossRef Medline](#)
- Reddy DS (2011) Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy. *Front Endocrinol (Lausanne)* 2:38. [CrossRef Medline](#)
- Reddy DS, Estes WA (2016) Clinical potential of neurosteroids for CNS disorders. *Trends Pharmacol Sci*. Advance online publication. Retrieved May 5, 2016. doi: 10.1016/j.tips.2016.04.003. [CrossRef Medline](#)
- Reddy DS, Jian K (2010) The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABA-A receptors. *J Pharmacol Exp Ther* 334:1031–1041. [CrossRef Medline](#)
- Reddy DS, Mohan A (2011) Development and persistence of limbic epileptogenesis are impaired in mice lacking progesterone receptors. *J Neurosci* 31:650–658. [CrossRef Medline](#)
- Reddy SD, Younus I, Clossen BL, Reddy DS (2015) Antiseizure activity of midazolam in mice lacking  $\delta$ -subunit extrasynaptic GABA<sub>A</sub> receptors. *J Pharmacol Exp Ther* 353:517–528. [CrossRef Medline](#)
- Ruiz A, Walker MC, Fabian-Fine R, Kullmann DM (2004) Endogenous zinc inhibits GABA<sub>A</sub> receptors in a hippocampal pathway. *J Neurophysiol* 91:1091–1096. [CrossRef Medline](#)
- Slevin JT, Kasarskis EJ, Vanaman TC, Zurini M (1986) Excitatory amino acids and divalent cations in the kindling model of epilepsy. *Adv Exp Med Biol* 203:587–598. [CrossRef Medline](#)
- Smart TG, Moss SJ, Xie X, Haganir RL (1991) GABA<sub>A</sub> receptors are differentially sensitive to zinc: dependence of subunit composition. *Br J Pharmacol* 103:1837–1839. [CrossRef Medline](#)
- Spigelman I, Li Z, Liang J, Cagetti E, Samzadeh S, Mihalek RM, Homanics GE, Olsen RW (2003) Reduced inhibition and sensitivity to neurosteroids in hippocampus of mice lacking GABA<sub>A</sub> receptor  $\delta$  subunit. *J Neurophysiol* 90:903–910. [CrossRef Medline](#)
- Stell BM, Brickley SG, Tang CY, Farrant M, Mody I (2003) Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by  $\delta$  subunit-containing GABA<sub>A</sub> receptors. *Proc Natl Acad Sci U S A* 100:14439–14444. [CrossRef Medline](#)
- Stórustovu SI, Ebert B (2006) Pharmacological characterization of agonists at  $\delta$ -containing GABA<sub>A</sub> receptors: functional selectivity of extrasynaptic receptors is dependent on the absence of  $\gamma_2$ . *J Pharmacol Exp Ther* 316:1351–1359. [CrossRef Medline](#)
- Takeda A, Hanajima T, Ijiri H, Ishige A, Iizuka S, Okada S, Oku N (1999) Release of zinc from the brain of El (epilepsy) mice during seizure induction. *Brain Res* 828:174–178. [CrossRef Medline](#)
- Villumsen IS, Wellendorph P, Smart TG (2015) Pharmacological characterization of murine  $\alpha 4\beta 1\delta$  GABAA receptors expressed in *Xenopus* oocytes. *BMC Neurosci* 16:8. [CrossRef Medline](#)
- Vogt K, Mellor J, Tong G, Nicoll R (2000) The actions of synaptically released zinc at hippocampal mossy fiber synapses. *Neuron* 26:187–196. [CrossRef Medline](#)
- Whissell PD, Lecker I, Wang DS, Yu J, Orser BA (2015) Altered expression of  $\delta$ GABA<sub>A</sub> receptors in health and disease. *Neuropharmacology* 88:24–35. [CrossRef Medline](#)
- Włodarczyk AI, Xu C, Song I, Doronin M, Wu YW, Walker MC, Semyanov A (2013) Tonic GABAA conductance decreases membrane time constant and increases EPSP-spike precision in hippocampal pyramidal neurons. *Front Neural Circuits* 7:1–8. [CrossRef Medline](#)
- Wu X, Gangisetty O, Carver CM, Reddy DS (2013) Estrous cycle regulation of extrasynaptic  $\delta$ -containing GABA-A receptor-mediated tonic inhibition and limbic epileptogenesis. *J Pharmacol Exp Ther* 346:146–160. [CrossRef](#)